Vorinostat in solid and hematologic malignancies

Vorinostat (Zolinza(®)), a histone deacetylase inhibitor, was approved by the US Food and Drug Administration in October 2006 for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma who have progressive, persistent or recurrent disease on or following two systemic th...

Descripción completa

Detalles Bibliográficos
Autores principales: Siegel, David, Hussein, Mohamad, Belani, Chandra, Robert, Francisco, Galanis, Evanthia, Richon, Victoria M, Garcia-Vargas, José, Sanz-Rodriguez, Cesar, Rizvi, Syed
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2731787/
https://www.ncbi.nlm.nih.gov/pubmed/19635146
http://dx.doi.org/10.1186/1756-8722-2-31

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2731787/
https://www.ncbi.nlm.nih.gov/pubmed/19635146
http://dx.doi.org/10.1186/1756-8722-2-31

Ejemplares similares